The Multiple Myeloma Market should see a stand-out year in 2020 | Fortune Business Insights™

 The global multiple myeloma market size is projected to reach USD 31 billion by the end of 2026. The high prevalence of the disease will emerge in favor of the companies operating in the market. According to a report published by Fortune Business Insights, titled “Multiple Myeloma Market Size, Share & Industry Analysis, By Drug Class (Immunomodulators, Proteasome Inhibitor, Anti-CD38 Monoclonal Antibody, Alkylating Agents, and Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies & Drug Stores, Online Pharmacies), and Regional Forecast, 2019-2026,” the market was worth USD 19.48 billion in 2018 and will exhibit a CAGR of 6.0% during the forecast period, 2019-2026.

For more information in the analysis of this report, visit: https://www.fortunebusinessinsights.com/multiple-myeloma-market-102693

Detailed Table of Content:

1.       Introduction

1.1.    Research Scope

1.2.    Market Segmentation

1.3.    Research Methodology

1.4.    Definitions and Assumptions

2.       Executive Summary

3.       Market Dynamics

3.1.    Market Drivers

3.2.    Market Restraints

3.3.    Market Opportunities

4.       Key Insights

4.1.    Prevalence of Multiple Myeloma - by Key Countries - 2018

4.2.    Pipeline Analysis

4.3.    Key Industry Developments

4.4.    Regulatory Scenario, by Key Regions

4.5.    Analysis Of Economic Burden of Multiple Myeloma Treatment

4.6.    New Product Launches

4.7.    Overview of Emerging Treatments for Multiple Myeloma

5.       Global Multiple Myeloma Market Analysis, Insights and Forecast, 2015-2026

5.1.    Key Findings / Summary

5.2.    Market Analysis, Insights and Forecast – By Drug Class

5.2.1. Immunomodulators

5.2.2. Proteasome Inhibitor

5.2.3. Anti-CD38 Monoclonal Antibody

5.2.4. Alkylating Agents

5.2.5. Others

5.3.    Market Analysis, Insights and Forecast – By Distribution Channel

5.3.1. Hospital Pharmacies

5.3.2. Retail Pharmacies & Drug Stores

5.3.3. Online Pharmacies

5.4.    Market Analysis, Insights and Forecast – By Region

5.4.1. North America

5.4.2. Europe

5.4.3. Asia Pacific

5.4.4. Latin America

5.4.5. Middle East & Africa

6.       North America Multiple Myeloma Market Analysis, Insights and Forecast, 2015-2026

6.1.    Key Findings / Summary

6.2.    Market Analysis – By Drug Class

6.2.1. Immunomodulators

6.2.2. Proteasome Inhibitor

6.2.3. Anti-CD38 Monoclonal Antibody

6.2.4. Alkylating Agents

6.2.5. Others

6.3.    Market Analysis – By Distribution Channel

6.3.1. Hospital Pharmacies

6.3.2. Retail Pharmacies & Drug Stores

6.3.3. Online Pharmacies

6.4.    Market Analysis – By Country

6.4.1. U.S.

6.4.2. Canada

7.       Europe Multiple Myeloma Market Analysis, Insights and Forecast, 2015-2026

7.1.    Key Findings / Summary

7.2.    Market Analysis – By Drug Class

7.2.1. Immunomodulators

7.2.2. Proteasome Inhibitor

7.2.3. Anti-CD38 Monoclonal Antibody

7.2.4. Alkylating Agents

7.2.5. Others

7.3.    Market Analysis – By Distribution Channel

7.3.1. Hospital Pharmacies

7.3.2. Retail Pharmacies & Drug Stores

7.3.3. Online Pharmacies

7.4.    Market Analysis – By Country/ sub-region

7.4.1. U.K.

7.4.2. Germany

7.4.3. France

7.4.4. Spain

7.4.5. Italy

7.4.6. Scandinavia

7.4.7. Rest of Europe

8.       Asia pacific Multiple Myeloma Market Analysis, Insights and Forecast, 2015-2026

8.1.    Key Findings / Summary

8.2.    Market Analysis – By Drug Class

8.2.1. Immunomodulators

8.2.2. Proteasome Inhibitor

8.2.3. Anti-CD38 Monoclonal Antibody

8.2.4. Alkylating Agents

8.2.5. Others

8.3.    Market Analysis – By Distribution Channel

8.3.1. Hospital Pharmacies

8.3.2. Retail Pharmacies & Drug Stores

8.3.3. Online Pharmacies

8.4.    Market Analysis – By Country/ sub-region

8.4.1. Japan

8.4.2. China

8.4.3. India

8.4.4. Australia

8.4.5. Southeast Asia

8.4.6. Rest of Asia Pacific

9.       Latin America Multiple Myeloma Market Analysis, Insights and Forecast, 2015-2026

9.1.    Key Findings / Summary

9.2.    Market Analysis – By Drug Class

9.2.1. Immunomodulators

9.2.2. Proteasome Inhibitor

9.2.3. Anti-CD38 Monoclonal Antibody

9.2.4. Alkylating Agents

9.2.5. Others

9.3.    Market Analysis – By Distribution Channel

9.3.1. Hospital Pharmacies

9.3.2. Retail Pharmacies & Drug Stores

9.3.3. Online Pharmacies

9.4.    Market Analysis – By Country/ sub-region

9.4.1. Brazil

9.4.2. Mexico

9.4.3. Rest of Latin America

10.   Middle East & Africa Multiple Myeloma Market Analysis, Insights and Forecast, 2015-2026

10.1.Key Findings / Summary

10.2.Market Analysis – By Drug Class

10.2.1.    Immunomodulators

10.2.2.    Proteasome Inhibitor

10.2.3.    Anti-CD38 Monoclonal Antibody

10.2.4.    Alkylating Agents

10.2.5.    Others

10.3.Market Analysis – By Distribution Channel

10.3.1.    Hospital Pharmacies

10.3.2.    Retail Pharmacies & Drug Stores

10.3.3.    Online Pharmacies

10.4.Market Analysis – By Country/ sub-region

10.4.1.    GCC Countries

10.4.2.    South Africa

10.4.3.    Rest of Middle East & Africa

Continued...